JP2022533436A5 - - Google Patents

Info

Publication number
JP2022533436A5
JP2022533436A5 JP2021569396A JP2021569396A JP2022533436A5 JP 2022533436 A5 JP2022533436 A5 JP 2022533436A5 JP 2021569396 A JP2021569396 A JP 2021569396A JP 2021569396 A JP2021569396 A JP 2021569396A JP 2022533436 A5 JP2022533436 A5 JP 2022533436A5
Authority
JP
Japan
Prior art keywords
compound
disease
pharmaceutically acceptable
formula
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021569396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533436A (ja
JP7687964B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/034434 external-priority patent/WO2020243027A1/en
Publication of JP2022533436A publication Critical patent/JP2022533436A/ja
Publication of JP2022533436A5 publication Critical patent/JP2022533436A5/ja
Priority to JP2025037274A priority Critical patent/JP2025090698A/ja
Application granted granted Critical
Publication of JP7687964B2 publication Critical patent/JP7687964B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021569396A 2019-05-24 2020-05-24 化合物、組成物、および使用方法 Active JP7687964B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025037274A JP2025090698A (ja) 2019-05-24 2025-03-10 化合物、組成物、および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852565P 2019-05-24 2019-05-24
US62/852,565 2019-05-24
PCT/US2020/034434 WO2020243027A1 (en) 2019-05-24 2020-05-24 Compounds, compositions, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025037274A Division JP2025090698A (ja) 2019-05-24 2025-03-10 化合物、組成物、および使用方法

Publications (3)

Publication Number Publication Date
JP2022533436A JP2022533436A (ja) 2022-07-22
JP2022533436A5 true JP2022533436A5 (https=) 2023-05-31
JP7687964B2 JP7687964B2 (ja) 2025-06-03

Family

ID=71078654

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021569396A Active JP7687964B2 (ja) 2019-05-24 2020-05-24 化合物、組成物、および使用方法
JP2025037274A Pending JP2025090698A (ja) 2019-05-24 2025-03-10 化合物、組成物、および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025037274A Pending JP2025090698A (ja) 2019-05-24 2025-03-10 化合物、組成物、および使用方法

Country Status (7)

Country Link
US (1) US20220332699A1 (https=)
EP (1) EP3976186A1 (https=)
JP (2) JP7687964B2 (https=)
AR (1) AR119010A1 (https=)
MA (1) MA56032A (https=)
TW (2) TW202523658A (https=)
WO (1) WO2020243027A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2848212C (en) 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
IL309208A (en) 2021-06-11 2024-02-01 Sage Therapeutics Inc Neuroactive steroid for the treatment of alzheimer's disease
CN113501787A (zh) * 2021-08-20 2021-10-15 黑龙江省科学院石油化学研究院 一种合成6-三氟甲基-3-甲基吲唑的方法
US20240189312A1 (en) * 2022-12-02 2024-06-13 Morehouse School Of Medicine Composition for treating acute brain injury or neurodegenerative disease, method of making, and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
JP2001500852A (ja) 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
US20100152160A1 (en) * 2008-12-12 2010-06-17 Khamrai Uttam Novel benzodioxane and benzoxazine derivatives useful as cc chemokine receptor ligands
US8642621B2 (en) * 2009-09-16 2014-02-04 The University Of Edinburgh (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use
AU2011247116B2 (en) * 2010-04-29 2015-12-03 The University Of Edinburgh 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1H - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -HSD1
AP2014007606A0 (en) * 2011-10-07 2014-05-31 Takeda Pharmaceutical 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
HUE039922T2 (hu) 2012-12-11 2019-02-28 Takeda Pharmaceuticals Co Heterociklusos vegyületek
EP2982666B1 (en) * 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
MX2022003845A (es) * 2019-09-30 2022-06-22 Actinogen Medical Ltd Tratamientos cognitivos medicinales.

Similar Documents

Publication Publication Date Title
JP2022533436A5 (https=)
US10689347B2 (en) Substituted heterocyclyl derivatives as CDK inhibitors
US9656975B2 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
JP2007533741A (ja) Ｂａｃｅ阻害剤
JP6574756B2 (ja) Ｂａｃｅ１阻害剤
KR20180008402A (ko) 릴루졸 전구약물 및 그의 용도
WO2010144647A1 (en) Nicotinamide compounds useful as kinase modulators
WO2014157653A1 (ja) 光学活性ジアミン誘導体の製造方法
US20210340121A1 (en) Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
CA2188427C (en) Neurotransmitter release enhancers
KR20150067188A (ko) 벤즈아미드
US8633190B2 (en) Spirolactam derivatives and uses of same
AU2019247885B2 (en) Substituted pyrazole derivatives as selective CDK12/13 inhibitors
KR20090129479A (ko) 화합물 2-히드록시-3-[5-(모르폴린-4-일메틸)피리딘-2-일]1ｈ-인돌-5-카르보니트릴 701의 신규 제조 방법
JP2023550654A5 (https=)
JP2017500287A (ja) Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体
US20230212142A9 (en) Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors
EP3215508A1 (en) Substituted 5-methyl-[1, 2, 4]triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors
CA3106354A1 (en) Amino-pyridinyl-azetidinyl-carboxamide derivatives and pharmaceutical compositions thereof useful as inhibitors of histone deacetylase
JP2024540318A5 (https=)
CA3106355A1 (en) (aminopyridinyl)pyrrolidinyl-1-carboxyamide derivatives and pharmaceutical compositions thereof useful as inhibitors of histone deacetylase
JP2022519639A5 (https=)
WO2025008732A1 (en) Novel compounds as modulators of il17
DE69530408T2 (de) Neue zwischenprodukte und verfahren zur herstellung von pyridin-derivaten
US9212165B2 (en) Bicarbocyclic and tricarbocyclic ethynyl derivatives and uses of same